1.	A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181202, NCT01525550
2.	Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001K24133E1, NCT01595009
3.	Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-2247, NCT00442533
4.	Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas Phase: Phase III Type: Diagnostic Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MKT-2012-nCLE-02, NCT01563133
5.	Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers Phase: Phase II, Phase I Type: Tissue collection/Repository Status: Active Age: Not specified Sponsor: Other Protocol IDs: 93-102, NCT00579163
6.	Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NU 11I03, NCI-2011-02939, STU00053541, NCT01465659
7.	Phase II Randomized Study of Capecitabine and Streptozocin With Versus Without Cisplatin in Patients With Unresectable or Metastatic Neuroendocrine Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRCA-CCTC-NET-01, EUDRACT-2004-005202-71, EU-207102, ISRCTN35124268, NCT00602082
8.	Capecitabine and Temozolomide for Neuroendocrine Cancers Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: AAAB3348, NCT00869050
9.	Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Phase: Phase II Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20070315, NCT00896454
10.	Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230D2203, 2008-007348-32, NCT00958841
11.	Phase II Study of Temsirolimus and Bevacizumab in Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Hepatocellular Carcinoma, Islet Cell Cancer, or Carcinoid Tumor (All permanently closed to enrollment except Islet Cell) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0845, MC0845, 8233, NCT01010126
12.	DOTA-TOC in Metastasized Neuroendocrine Cancer Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: MAW002, NCT00978211
13.	Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-09-090, NCT01099540
14.	Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: EudraCT 2006-004748-22, NCT01203306
15.	Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070145, 2007-005628-34, NCT01215578
16.	177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 78,256, NCT01237457
17.	Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16438, CSOM230DUS23T, NCT01253161
18.	Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230I2201, 2010-023183-40, NCT01374451
19.	Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 11-274, NCT01466036
20.	Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: END0012, NCI-2011-03497, SU-10282011-8571, NCT01525082
21.	Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235Z2401, 2012-000769-19, NCT01628913
22.	Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HE 67/12, 2011-006160-48, NCT01648465
23.	BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235F2201, 2012-000675-16, NCT01658436
24.	68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Phase: Phase II Type: Diagnostic Status: Approved-not yet active Age: 18 to 90 Sponsor: Other Protocol IDs: 2012-000994-22, NCT01673906
25.	Phase I Study of Yttrium Y 90-DOTA-tyr3-Octreotide in Children With Advanced or Refractory Somatostatin Receptor-Positive Tumors Phase: Phase I Type: Treatment Status: Active Age: 2 to 25 Sponsor: NCI Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086